Benzinga · Jul 10, 2026
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventory for the commercial launch of REZENOPY.
SC
NASDAQ · SCNX
Scienture Holdings, Inc.
Healthcare · Medical - Healthcare Information Services
$3.42
Down-$0.03 (-0.87%)
Updated Nov 5, 2026, 5:24 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.44M
- P/E ratio
- -0.43
- Dividend yield
- 0.00%
- 52-week range
- $0.24 – $6.85
- Volume
- 14.16K
- Avg. volume
- 22.01M
Price performance · SCNX
SCNX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
SCNX closed at $3.42 after 21 trading sessions, down 17.19% for the selected period.
- Last close
- $3.42
- Period change
- -17.19%
- Period low
- $2.77
- Period high
- $4.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $3.29 | $3.47 | $3.29 | $3.42 | 14.16K |
| Nov 3, 2026 | $3.20 | $3.45 | $3.13 | $3.45 | 12.71K |
| Nov 2, 2026 | $3.13 | $3.245 | $3.13 | $3.23 | 6.14K |
| Oct 30, 2026 | $3.42 | $3.42 | $3.17 | $3.22 | 11.38K |
| Oct 29, 2026 | $3.31 | $3.68 | $3.31 | $3.49 | 59.04K |
| Oct 28, 2026 | $3.10 | $3.40 | $3.10 | $3.40 | 41.97K |
| Oct 27, 2026 | $2.965 | $3.23 | $2.8201 | $3.23 | 37.3K |
| Oct 26, 2026 | $3.04 | $3.04 | $2.89 | $2.93 | 16.86K |
| Oct 23, 2026 | $2.76 | $2.89 | $2.64 | $2.88 | 69.93K |
| Oct 22, 2026 | $2.80 | $2.91 | $2.70 | $2.77 | 31.67K |
| Oct 21, 2026 | $3.04 | $3.095 | $2.85 | $2.905 | 25.72K |
| Oct 20, 2026 | $2.9884 | $3.0508 | $2.9212 | $3.05 | 22.49K |
| Oct 19, 2026 | $3.39 | $3.39 | $2.81 | $2.92 | 76.14K |
| Oct 16, 2026 | $3.38 | $3.42 | $3.25 | $3.36 | 24.54K |
| Oct 15, 2026 | $3.68 | $3.68 | $3.21 | $3.38 | 52.66K |
| Oct 14, 2026 | $3.33 | $3.52 | $3.27 | $3.35 | 39.42K |
| Oct 13, 2026 | $3.93 | $3.93 | $3.24 | $3.24 | 468.21K |
| Oct 12, 2026 | $3.79 | $3.91 | $3.5806 | $3.91 | 37.7K |
| Oct 9, 2026 | $3.79 | $3.84 | $3.6505 | $3.76 | 32.86K |
| Oct 8, 2026 | $4.26 | $4.26 | $3.76 | $3.86 | 70.95K |
| Oct 7, 2026 | $3.85 | $4.20 | $3.6487 | $4.13 | 108.71K |
Latest SCNX news
The latest Smart Investors Daily articles mentioning SCNX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SCNX research
Overview
Company profile and research snapshot.
Company profile
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | Maxim Group | Buy | — |
| Feb 24, 2026 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 9, 2026
Scienture To Begin Shiptments Of REZENOPY Nasal Spray 10mg To U.S. Pharmaceutical Wholesalers Later This Month
The Company expects REZENOPY™ to become commercially available for purchase in August. The Company is working with its wholesale distribution partners in preparation for nationwide commercial availability. The initial
Benzinga · Mar 11, 2026
Scienture Holdings shares are trading higher after the company formalized multiple commercial Group Purchasing Organization to increase the availability of its Rezenopy naloxone spray to reverse opioid overdose.
Benzinga · Mar 11, 2026
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market
Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US institutions and first responders.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
